T Cell Receptor (TCR) Based Antibody Market Report 2025

The T-cell receptor (TCR)-based antibody market size has grown rapidly in recent years. It will grow from $2.57 billion in 2024 to $3.04 billion in 2025 at a compound annual growth rate (CAGR) of 18.1%. The growth during the historic period can be attributed to the increasing demand for targeted cancer therapies, a growing focus on intracellular antigen targeting, a rise in clinical research on T cell receptor-based modalities, expanding investments in immunotherapy platforms, and the rising adoption of personalized medicine approaches.

The T-cell receptor (TCR)-based antibody market size is expected to see rapid growth in the next few years. It will grow to $5.84 billion in 2029 at a compound annual growth rate (CAGR) of 17.7%. The growth during the forecast period can be attributed to the increasing demand for precision and targeted therapies, a growing focus on neoantigen targeting for cancer treatment, a rising number of orphan drug approvals for rare cancers, expanding public and private funding in immuno-oncology, and heightened emphasis on neoantigen targeting. Key trends in the forecast period include advancements in T cell receptor-mimic antibody design, development of bispecific T cell receptor-antibody formats, innovations in major histocompatibility complex-restricted antigen targeting, progress in artificial intelligence-driven epitope discovery, and the creation of off-the-shelf T cell receptor-based therapeutics.

The rising prevalence of cancer is anticipated to drive growth in the T-cell receptor-based antibody market in the coming years. Cancer prevalence refers to the total number of individuals, both newly and previously diagnosed, who are living with a history of cancer at a given time. This increase is largely fueled by lifestyle-related risk factors, including poor diet, smoking, alcohol consumption, and exposure to environmental pollutants, which elevate the likelihood of developing various cancers. T-cell receptor-based antibodies enhance cancer therapy by specifically targeting tumor cells, improving treatment precision. They help the immune system recognize and eliminate cancer cells more effectively, boosting therapeutic efficacy while minimizing side effects. For example, in July 2024, the Australian Institute of Health and Welfare, a government agency in Australia, reported that 160,570 cancer cases were diagnosed in 2022, up by 3,789 cases from 156,781 in 2021. Consequently, the growing prevalence of cancer is contributing to the expansion of the T-cell receptor-based antibody market.

Leading companies in the T-cell receptor-based antibody sector are focusing on developing innovative products, such as TCR mimic antibodies, to enhance therapeutic precision, efficacy, and expand treatment options for cancer and other diseases. TCR mimic antibodies are engineered to recognize intracellular antigens presented by MHC molecules, similar to natural T-cell receptors, enabling targeted immune responses against diseased cells. For instance, in September 2022, Biocytogen Pharmaceuticals (Beijing) Co. Ltd., a biotechnology company based in China, partnered with Guangzhou FineImmune Biotechnology Co. Ltd., also based in China, to launch TCR-mimic antibody-based cell therapies for cancer treatment. Biocytogen utilized its proprietary RenMice platform to generate fully human antibodies targeting specific peptide-MHC complexes, while FineImmune contributed expertise in T-cell engager and cell therapy development. This collaboration aims to advance next-generation immunotherapies with improved specificity and reduced off-target effects, offering potential new treatment options for patients with difficult-to-treat cancers.

In April 2025, DAAN Biotherapeutics Inc., a South Korean biotechnology company, partnered with GC Cell Corporation to advance tumor antigen-specific antibody technologies. The collaboration focuses on developing highly specific and effective CAR-T and CAR-NK cell therapies targeting solid tumors, aiming to improve patient outcomes and minimize side effects. GC Cell Corporation, also based in South Korea, specializes in T-cell receptor-based antibody technologies.

Major players in the t cell receptor (tcr) based antibody market are Pfizer Inc., Bristol-Myers Squibb Company, Novartis AG, GSK plc, Amgen Inc., Bio-Rad Laboratories Inc., GenScript Biotech Corporation, Biocytogen Pharmaceuticals Co. Ltd., Abcam plc, Immunocore Holdings plc, Xencor Inc., Fate Therapeutics Inc., Eureka Therapeutics Inc., Proteintech Group Inc., Santa Cruz Biotechnology Inc., Creative Biolabs Inc., TScan Therapeutics Inc., Alloy Therapeutics Inc., Affini-T Therapeutics Inc., Medigene AG, 3T Biosciences Inc., Nona Biosciences, Alithea Biotechnology GmbH, Nextera Therapeutics Inc., TCRCure Biopharma Ltd.

North America was the largest region in the T cell receptor (TCR)-based antibody market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in T cell receptor-(TCR) based antibody market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the T cell receptor-(TCR) based antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

T cell receptor-based antibodies are engineered antibodies designed to mimic the specificity of T cell receptors, enabling them to recognize and bind to intracellular antigens presented by major histocompatibility complex (MHC) molecules on the cell surface. These antibodies facilitate targeted therapies by accessing a wider range of antigens that conventional antibodies typically cannot reach.

The primary types of T cell receptor-based antibodies include monoclonal antibodies, polyclonal antibodies, bispecific antibodies, and conjugated antibodies. Monoclonal antibodies are laboratory-produced molecules engineered to bind specifically to a single target antigen, imitating the immune system’s ability to combat harmful pathogens such as viruses or cancer cells. They target a variety of antigens, including tumor-associated antigens, viral antigens, autoimmune antigens, and more. Therapeutic strategies include cytotoxic T-cell therapies, regulatory T-cell therapies, and dual-targeting therapies. Applications of these antibodies span cancer immunotherapy, infectious diseases, autoimmune disorders, transplant rejection, and diagnostic testing, serving end-users such as hospitals, research institutes, specialty clinics, and others.

The T cell receptor-based antibody market research report is one of a series of new reports that provides T cell receptor-based antibody market statistics, including T cell receptor-based antibody industry global market size, regional shares, competitors with a T cell receptor-based antibody market share, detailed T cell receptor-based antibody market segments, market trends and opportunities, and any further data you may need to thrive in the T cell receptor-based antibody industry. This T cell receptor-based antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The T cell receptor-(TCR) based antibody market consists of revenues earned by entities by providing services such as preclinical and clinical testing services, cell-based assay development services, and antigen discovery and validation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The T cell receptor-based antibody market also includes sales of engineered antibody-drug conjugates, cell engagers, diagnostic reagents, and therapeutic vaccines. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.